Breast cancer:: from estrogen to androgen receptor

被引:120
作者
Andò, S
De Amicis, F
Rago, V
Carpino, A
Maggiolini, M
Panno, ML
Lanzino, M
机构
[1] Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, CS, Italy
[2] Univ Calabria, Dept Cell Biol, I-87036 Arcavacata Di Rende, CS, Italy
关键词
breast cancer; estrogen; androgen;
D O I
10.1016/S0303-7207(02)00105-3
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To investigate the link existing between androgens and human breast cancer, the hormonal milieu present in pre- and postmenopausal women has been translated in an in vitro model utilizing a hormone dependent breast cancer cell line MCF-7 exposed to DHEA, DHEAS, androstenediol, T, DHT with or w/o E-2. DHEAS and androstenediol stimulate the growth of MCF-7 cell line but reduce cell proliferation induced by E-2 (1 nM). T and DHT (1-100 nM) instead inhibit MCF-7 cell proliferation independently on E-2 presence. When we focused our study on the most powerful androgen, DHT alone (100 nM) consistently inhibits MCF-7 cell proliferation by 50% of the basal growth rate and counteracts E-2 proliferative action by 68%. These data correlate well with cell cycle analysis showing an enhanced number of cells in G(0)/G(1) phase after 6 days of DHT treatment. Upon prolonged DHT exposure, Western blotting analysis shows a markedly increased AR content, while immunohistochemistry indicates that it was mostly translocated into the nucleus. So we assumed that the enhanced activation of the AR might inhibit MCF-7 cells proliferation. This assumption is corroborated by the fact that the inhibitory effects induced by DHT on MCF-7 cell proliferation are abrogated in the presence of hydroxyflutamide. Therefore to better investigate the role of AR in inhibiting E-2 action at genomic level, MCF-7 cells were transiently cotransfected with the reporter plasmid XETL carrying firefly luciferase sequence under the control of an estrogen responsive element and the full length AR or with an AR carrying a mutation (Cis 574 --> Arg 574) which abolishes its binding to DNA. The over-expression of the AR markedly decreases E-2 signalling which furthermore appears inhibited by simultaneous exposure to DHT but reversed by addition of hydroxyflutamide. The inhibitory effect was no longer noticeable when MCF-7 cells were cotransfected with XETL and the mutant AR. Taken together these data demonstrate that gonadal androgens antagonize MCF-7 proliferation induced by E-2. This seems to be related to the inhibitory effects of the over-expressed AR on E-2 genomic action. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 50 条
  • [1] Post-menopausal breast cancer: from estrogen to androgen receptor
    Majumder, Avisek
    Singh, Mahavir
    Tyagi, Suresh C.
    ONCOTARGET, 2017, 8 (60) : 102739 - 102758
  • [2] Expression of Androgen Receptor in Estrogen Receptor-positive Breast Cancer
    Agrawal, Anil
    Ziolkowski, Piotr
    Grzebieniak, Zygmunt
    Jelen, Michal
    Bobinski, Piotr
    Agrawal, Siddarth
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (08) : 550 - 555
  • [3] Androgen receptor in estrogen receptor positive breast cancer: Beyond expression
    Basile, Debora
    Cinausero, Marika
    Iacono, Donatella
    Pelizzari, Giacomo
    Bonotto, Marta
    Vitale, Maria Grazia
    Gerratana, Lorenzo
    Puglisi, Fabio
    CANCER TREATMENT REVIEWS, 2017, 61 : 15 - 22
  • [4] Androgen Receptor in Breast Cancer: From Bench to Bedside
    Chen, Mengyao
    Yang, Yunben
    Xu, Kai
    Li, Lili
    Huang, Jian
    Qiu, Fuming
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [5] Role of Androgen Excess in the Development of Estrogen Receptor-positive and Estrogen Receptor-negative Breast Cancer
    Secreto, Giorgio
    Zumoff, Barnett
    ANTICANCER RESEARCH, 2012, 32 (08) : 3223 - 3228
  • [6] Estrogen receptor β in the breast:: role in estrogen responsiveness and development of breast cancer
    Gustafsson, JÅ
    Warner, M
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2000, 74 (05) : 245 - 248
  • [7] Androgen receptor and estrogen receptor variants in prostate and breast cancers
    Lopez, Jose C. Valentin
    Lange, Carol A.
    Dehm, Scott M.
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2024, 241
  • [8] Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer
    Tokunaga, Eriko
    Hisamatsu, Yuichi
    Taketani, Kenji
    Yamashita, Nami
    Akiyoshi, Sayuri
    Okada, Satoko
    Tanaka, Kimihiro
    Saeki, Hiroshi
    Oki, Eiji
    Aishima, Shinichi
    Oda, Yoshinao
    Morita, Masaru
    Maehara, Yoshihiko
    CANCER MEDICINE, 2013, 2 (06): : 763 - 773
  • [9] Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status
    Noh, Songmi
    Kim, Ji-Ye
    Koo, Ja Seung
    TUMOR BIOLOGY, 2014, 35 (08) : 8179 - 8192
  • [10] Androgen receptor CAG repeat length and estrogen receptor status in postmenopausal breast cancer prognosis
    Cogliati, Patrizia
    Ciniselli, Chiara Maura
    Agresti, Roberto
    Paolini, Biagio
    Bonini, Chiara
    Radice, Paolo
    Krogh, Vittorio
    Verderio, Paolo
    Venturelli, Elisabetta
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2015, 30 (04) : E418 - E424